Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/00003246-199901000-00058 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Propofol, Triglycerides, and Acute Pancreatitis: A Multi-Center Epidemiologic Analysis.
Ann Am Thorac Soc
October 2024
Mayo Clinic Division of Pulmonary and Critical Care Medicine, Rochester, Minnesota, United States;
Article Synopsis
- Propofol is frequently used as a sedative for critically ill adults on mechanical ventilation, but its link to elevated triglyceride levels and acute pancreatitis remains unclear.
- The study observed over 11,000 ICU patients receiving propofol, finding that about 21.7% developed hypertriglyceridemia, and those with high triglycerides had a significantly increased risk of pancreatitis.
- Despite the association between triglyceride levels and pancreatitis, acute pancreatitis is rare in this population, suggesting other contributing factors may be involved.
Introduction: Propofol is a widely used sedative-hypnotic agent for critically-ill patients requiring invasive mechanical ventilation (IMV). Despite its clinical benefits, propofol is associated with increased risks of hypertriglyceridemia. Early identification of patients at risk for propofol-associated hypertriglyceridemia is crucial for optimizing sedation strategies and preventing adverse outcomes.
View Article and Find Full Text PDFParameters Predictive of Propofol-Associated Acute Pancreatitis in Critically Ill Patients with COVID-19 Pneumonia: A Retrospective Cohort Study.
J Intensive Care Med
January 2025
Department of Medicine, St. Elizabeth's Medical Center, Boston, MA, USA.
Background: Propofol, a commonly used agent for short- and long-term sedation, is associated with acute pancreatitis. The main indirect mechanism of propofol-associated acute pancreatitis is by inducing hypertriglyceridemia. Patients with severe coronavirus disease 2019 (COVID-19) pneumonia often require prolonged mechanical ventilation and sedation.
View Article and Find Full Text PDFFospropofol disodium versus propofol for long-term sedation during invasive mechanical ventilation: A pilot randomized clinical trial.
J Clin Anesth
August 2024
Department of Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China. Electronic address:
Study Objective: Fospropofol disodium is a propofol prodrug that is water-soluble and has a reduced risk of bacterial contamination and hypertriglyceridemia compared with propofol. Prior to implementing a large randomized trial, we investigated the feasibility, initial efficacy, and safety of fospropofol disodium compared with propofol in long-term mild-to-moderate sedation in intensive care units (ICUs).
Design: Single-centered, prospective, unblind, randomized, parallel-group clinical trial.
Incidence of Hypertriglyceridemia in Patients on Propofol, Clevidipine, or Both.
Ann Pharmacother
December 2024
College of Pharmacy, Department of Clinical Pharmacy and Translational Science, The University of Tennessee Health Science Center, Knoxville, TN, USA.
Background: Propofol and clevidipine (PC) are commonly used in the treatment of critically ill patients. While both medications are lipid emulsions, there is limited evidence concerning the incidence of hypertriglyceridemia (HTG) when these agents are used individually or concurrently.
Objective: The objective of this study is to determine the effects of propofol, clevidipine, or concurrent PC on triglycerides (TGs) and related outcomes in critically ill adults.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!